Drug Topics
APRIL 15, 2024
In the United States, 12 million adults suffer from co-occurring chronic pain and anxiety or depression. Erasing stigmas, educating patients, and tailoring interventions can help to improve outcomes.
PharmaVoice
APRIL 15, 2024
The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 15, 2024
A string of thefts at local pharmacies has spurred the DEA to issue warnings and share tips for independent pharmacists to keep their stores secure.
STAT
APRIL 15, 2024
Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch her on launching a large company dedicated to tackling the world’s worst pathogens. “This is a crazy idea,” Sato said. Nelsen, managing director of ARCH Venture, had made a name and fortune off crazy ideas, but generally it was the science that sounded crazy: engineering cells to cure cancer, finding drugs to slow aging.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
APRIL 15, 2024
A study from the Children’s Hospital of Philadelphia found that a positive PCR test was not associated with an increased risk of a new asthma diagnosis in patients ages 1 to 16.
STAT
APRIL 15, 2024
The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., surged to 36% from just 5% during the first week of April, thanks to the expanding reach that CVS Health has over the prescription drug market. The big jump was attributed to one particular biosimilar called Hyrimoz, which is manufactured by Sandoz, a unit of Novartis that is a leading supplier of generic and biosimilar medicines.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
APRIL 15, 2024
The impact pharmacist-led research on oncology pharmacy practice in the field of oncology is undeniable.
Drug Topics
APRIL 15, 2024
See what's trending in pharmacy with a preview of the Total Pharmacy April issue.
STAT
APRIL 15, 2024
Boys aren’t the only people who develop attention-deficit/hyperactivity disorder (ADHD). It also affects girls and young women and adults of both genders. Yet females with ADHD are chronically underdiagnosed and undertreated. Individuals with this condition die about 10 years earlier than those without it. They are also up to three times more likely to experience a variety of nonfatal negative life events, such as serious car accidents, unintended teen pregnancy, episodes of anxiety and d
PharmaVoice
APRIL 15, 2024
As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 15, 2024
CHICAGO — The split between Dana-Farber Cancer Institute and Mass General Brigham has been messy. Some people who don’t see breakups coming wonder what went wrong, and maybe channel the sorrow into a love ballad. But Mass General Brigham is taking a different tack — it’s simply getting over it. The $20 billion nonprofit hospital system is now plotting out how its cancer programs will look in a post-Dana-Farber world.
Fierce Healthcare
APRIL 15, 2024
Elevance Health is teaming up with private equity firm Clayton, Dubilier & Rice in its latest bid to expand access to advanced primary care. | Elevance Health is teaming up with private equity firm Clayton, Dubilier & Rice in its latest bid to expand access to advanced primary care.
pharmaphorum
APRIL 15, 2024
Psychedelic treatments for conditions like PTSD using substances like MDMA are on the brink of approval, but there are still unanswered questions surrounding their effectiveness and potential risks. Learn more here.
STAT
APRIL 15, 2024
Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome, supporting the company’s decision to acquire its development partner two years ago. Ultragenyx is one of the few companies developing a treatment for Angelman syndrome , a genetic condition that causes delayed development, problems with speech and balance, mental disability, and sometimes seizures.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
APRIL 15, 2024
Opill is a nonprescription, progestin-only contraceptive pill, with nearly 50 years of use and data supporting the safety and effectiveness of progestin-only pills.
STAT
APRIL 15, 2024
Telehealth company Cerebral will limit the consumer health data it uses for advertising purposes under a new order announced by the Federal Trade Commission Monday. Cerebral, a startup best known for dispensing counseling services and prescriptions for conditions like anxiety and depression, has also agreed to pay $7 million to resolve charges that it disclosed customers’ personal health information to third parties for ads, and that it did not honor its promise to make cancellation easy
pharmaphorum
APRIL 15, 2024
Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.
Fierce Healthcare
APRIL 15, 2024
Virtual mental health startup Cerebral has agreed to pay the government more than $7 million, abide by a “first-of-its-kind” restriction on the handling of consumers’ sensitive information and rewo | The embattled mental health startup had inappropriately shared 3.2 million people's sensitive information, upheld "sloppy security practices" and slow-walked consumers trying to cancel services, the FTC said.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
APRIL 15, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, because that oh-so familiar routine of phone calls, online meetings, and rushing about has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup or three of stimulation.
Fierce Healthcare
APRIL 15, 2024
Houston’s Memorial Hermann-Texas Medical Center is working to resume liver and kidney transplant programs that were paused amid evidence that a head physician had made “inappropriate” alterati | Houston’s Memorial Hermann-Texas Medical Center's liver and kidney transplant programs have been suspended for several days. The organization said it's reached out to affected patients and is working to "quickly" restart the programs, but as of Monday offered no potential timeline.
Pharmacy Times
APRIL 15, 2024
There was no difference observed between adalimumab (Humira; AbbVie) and adalimumab-aacf (Idacio; Fresenius Kabi) for those who switched to the biosimilar.
Fierce Healthcare
APRIL 15, 2024
Insurers Humana, Centene and Elevance Health were selected as the three statewide Medicaid contract awardees in Florida on April 12. | Just three insurers earned statewide contracts for Florida's state-run managed care program, but UnitedHealth, Aetna and Molina were not selected.
The Checkup by Singlecare
APRIL 15, 2024
While bananas might not be the trendiest fruit (unless you count Andy Warhol’s version), they’re rightfully regarded as one of the original superfoods. They contain carbohydrates, soluble fiber, vitamin C—which helps protect against free radicals—vitamin B6, provitamin A, potassium, and magnesium. This powerful combination of essential nutrients makes the bright yellow fruit a great choice for people who are looking to maintain a healthy weight, lower blood pressure, improve skin health, and mor
pharmaphorum
APRIL 15, 2024
Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors to the board. In an open letter, the hedge fund accuses Novavax’s leadership of squandering its “many significant competitive advantages and sizeable market opportunity” due to “self-inflicted problems” under the current team led by chief executive John Jacobs.
Pharmacy Times
APRIL 15, 2024
Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.
pharmaphorum
APRIL 15, 2024
Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings for earlier use of the drug in the treatment pathway.
Pharmacy Times
APRIL 15, 2024
Although the vaccine has not yet been tested in humans, it demonstrated 100% efficacy in protecting primates who were injected with human Marburg virus disease.
STAT
APRIL 15, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. Anne Klibanski on the Dana-Farber split Mass General Brigham didn’t foresee the breakup with Dana-Farber Cancer Institute. But there won’t be any texts begging Dana-Farber to come back.
pharmaphorum
APRIL 15, 2024
The advancement of medicine is dependent on secure pharmaceutical supply chains. Discover why ensuring the security of these chains is crucial for the development and distribution of life-saving medications.
Pharmaceutical Commerce
APRIL 15, 2024
Results of the trial suggest that early intervention for intracerebral hemorrhage using parafascicular surgery were safe.
pharmaphorum
APRIL 15, 2024
Life sciences service provider (and pharmaphorum parent company) Eversana has completed the integration of Healthware Group, the Italy-based global agency and consultancy it acquired in October. The group will now be known as Eversana Intouch Healthware and will operate as Eversana’s sixth full-service affiliate.
Pharmaceutical Commerce
APRIL 15, 2024
The latest news for pharma industry insiders.
pharmaphorum
APRIL 15, 2024
Up to one in six people in eight industrialised nations could be suffering from chronic kidney disease (CKD) by 2032, with dire consequences for “patients, [the] planet, and economies,” says a new study.
Expert insights. Personalized for you.
503 
Let's personalize your content